Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

We have engineered brewer's yeast as a general platform for de novo synthesis of diverse β-lactam nuclei starting from simple sugars, thereby enabling ready access to a number of structurally different antibiotics of significant pharmaceutical importance. The biosynthesis of β-lactam nuclei has received much attention in recent years, while rational engineering of non-native antibiotics-producing microbes to produce β-lactam nuclei remains challenging. Benefited by the integration of heterologous biosynthetic pathways and rationally designed enzymes that catalyze hydrolysis and ring expansion reactions, we succeeded in constructing synthetic yeast cell factories which produce antibiotic cephalosporin C (CPC, 170.1 ± 4.9 μg/g DCW) and the downstream β-lactam nuclei, including 6-amino penicillanic acid (6-APA, 5.3 ± 0.2 mg/g DCW), 7-amino cephalosporanic acid (7-ACA, 6.2 ± 1.1 μg/g DCW) as well as 7-amino desacetoxy cephalosporanic acid (7-ADCA, 1.7 ± 0.1 mg/g DCW). This work established a Saccharomyces cerevisiae platform capable of synthesizing multiple β-lactam nuclei by combining natural and artificial enzymes, which serves as a metabolic tool to produce valuable β-lactam intermediates and new antibiotics. Copyright © 2022 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.


Dameng Yang, Wencheng Su, Yingying Jiang, Shushan Gao, Xiangying Li, Ge Qu, Zhoutong Sun. Biosynthesis of β-lactam nuclei in yeast. Metabolic engineering. 2022 Jul;72:56-65

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35245651

View Full Text